3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
13
Prostatic Neoplasms
9
Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Myeloid, Acute
4
Myelodysplastic Syndromes
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Cardiovascular Diseases
3
Cardiotoxicity
3
Triple Negative Breast Neoplasms
2
Polycystic Ovary Syndrome
2
Ovarian Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Leukemia
2
Kidney Neoplasms
2
Heart Failure
2
Endometrial Hyperplasia
2
Carcinoma, Renal Cell
2
Waldenstrom Macroglobulinemia
1
Venous Thrombosis
1
Urogenital Neoplasms
1
Smoking
1
Sarcoma
1
Rectal Neoplasms
1
Pulmonary Disease, Chronic Obstructive
1
Pancreatic Neoplasms
1
Overall Survival
1
Ototoxicity
1
Interventions
Propranolol
2
daratumumab
1
Watchful Waiting
1
Surgical Procedures, Operative
1
Simvastatin
1
Observation
1
DNA
1
Atorvastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hemangioma, Cavernous, Central Nervous System
×
Atorvastatin
×
Clear all
NCT02603328
2025-08-22
AT CASH EPOC
University of Chicago
Phase 1/2
Completed
80 enrolled
19 charts